ACXP Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to Acurx Pharmaceuticals's net margin of 21.68%. Acurx Pharmaceuticals's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

Acurx Pharmaceuticals has a consensus price target of $5.70, signalling upside risk potential of 1104.55%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.08%. Given that Acurx Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Acurx Pharmaceuticals is more attractive than Eli Lilly and.

Acurx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Acurx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Acurx Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Acurx Pharmaceuticals quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Acurx Pharmaceuticals's net income of -$2.1M is lower than Eli Lilly and's net income of $2.8B. Notably, Acurx Pharmaceuticals's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 64.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acurx Pharmaceuticals is -- versus 14.62x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Acurx Pharmaceuticals's net margin of -49.65%. Acurx Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Acurx Pharmaceuticals has a consensus price target of $5.70, signalling upside risk potential of 1104.55%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 22.83%. Given that Acurx Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Acurx Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Acurx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Acurx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acurx Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Acurx Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Acurx Pharmaceuticals's net income of -$2.1M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Acurx Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acurx Pharmaceuticals is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Acurx Pharmaceuticals's net margin of 26.7%. Acurx Pharmaceuticals's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Acurx Pharmaceuticals has a consensus price target of $5.70, signalling upside risk potential of 1104.55%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 28.32%. Given that Acurx Pharmaceuticals has higher upside potential than Regeneron Pharmaceuticals, analysts believe Acurx Pharmaceuticals is more attractive than Regeneron Pharmaceuticals.

Acurx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

Acurx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.31% to investors and pays a quarterly dividend of $0.88 per share. Acurx Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Acurx Pharmaceuticals quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Acurx Pharmaceuticals's net income of -$2.1M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Acurx Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acurx Pharmaceuticals is -- versus 4.60x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Acurx Pharmaceuticals's net margin of --. Acurx Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

Acurx Pharmaceuticals has a consensus price target of $5.70, signalling upside risk potential of 1104.55%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1294.42%. Given that Theriva Biologics has higher upside potential than Acurx Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Acurx Pharmaceuticals.

Acurx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Acurx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acurx Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Acurx Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Acurx Pharmaceuticals's net income of -$2.1M is higher than Theriva Biologics's net income of -$4.3M. Notably, Acurx Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acurx Pharmaceuticals is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.